NEW YORK, NY - 
(NewMediaWire) - April 10, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers or acquirers of the common stock of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) between February 10, 2023 and February 28, 2024 (the “Class Period”). Click Here to Join Investigation.
If you are a member of the proposed Class, you may move the court no later than May 20, 2024 to serve as lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process.
According to the complaint, on February 13, 2024, investors began to learn the truth when Chemours announced that the Company was delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal control over financial reporting as of December 31, 2023. According to the Company, the delay was necessary “because [the Company] needs additional time to complete its year-end reporting process” and “is evaluating its internal control over financial reporting. . .”
Following this news, the price of Chemours stock fell $3.85 per share, about 12.6%, to close at $26.64 per share on February 14, 2024.
Then, according to the complaint, before the market opened on February 29, 2024, Chemours issued a press release announcing that it had placed three executives, including the Company’s CEO and CFO, on administrative leave pending the completion of the internal review being overseen by the Audit Committee of the Board of Directors with the assistance of independent outside counsel. Additionally, according to the Company, the scope of the internal review “includes the processes for reviewing reports made to the Chemours Ethics Hotline” and Chemours’ “practices for managing working capital, including the related impact on metrics within the Company’s incentive plans [and] certain non-GAAP metrics.” Additionally, Chemours indicated that “the Company is evaluating one or more potential material weaknesses in its internal control over financial reporting as of December 31, 2023 with respect to maintaining effective controls related to the control environment, including the effectiveness of the ‘tone at the top’ set by certain members of senior management . . .”
Following this news, the price of Chemours stock fell $9.05 per share, or 31.5%, to close at $19.67 per share on February 29, 2024.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
